Dr. Elliott Sigal is a former Executive Vice President and Director of Bristol-Myers Squibb, and served as Chief Scientific Officer and President of R&D for BMS from 2004 until 2013. He was a principal architect of BMS’ successful Biopharma Transformation Strategy and was instrumental in increasing R&D productivity, developing BMS’ strategy in biologics and acquiring external innovation in Bristol’s String of Pearls initiative. Among his accomplishments in various therapeutic areas was building BMS research into a lead position in the promising area of immuno-oncology. Under his leadership, fourteen new medicines for a broad range of therapeutic indications have come to market, including the major blockbusters Sprycel (Leukemia), Eliquis (Anticoagulant), Orencia (Rheumatoid Arthritis) and Yervoy, the first approved immune checkpoint inhibitor for cancer immunotherapy. Dr. Sigal currently serves as a Venture Partner and Senior Advisor to the healthcare team of New Enterprise Associates and is a member of the Board of Directors for the Mead Johnson Nutrition Company, Spark Therapeutics, Adaptimmune and the Melanoma Research Alliance. Dr. Sigal received his M.D. from the University of Chicago and trained in Internal Medicine and Pulmonary Medicine at the University of California, San Francisco. Prior to medical school he studied engineering at Purdue University, where he received a B.S., M.S., and Ph.D.